GSK teams up with US researchers in bid to 'cure HIV'
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline is to invest $4m a year for five years to fund a new HIV research center focused on discovering a cure for HIV/AIDS at the University of North Carolina at Chapel Hill, and a jointly owned new company called Qura Therapeutics which will handle the business side of the partnership.